A Reversal for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Is Not Near. The Stock Has Rise in Shorts

December 6, 2017 - By Marie Mckinney

 A Reversal for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Is Not Near. The Stock Has Rise in Shorts

The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) registered an increase of 1.3% in short interest. ADMP’s total short interest was 2.19 million shares in December as published by FINRA. Its up 1.3% from 2.16M shares, reported previously. With 645,200 shares average volume, it will take short sellers 3 days to cover their ADMP’s short positions. The short interest to Adamis Pharmaceuticals Corporation’s float is 13.01%.

The stock decreased 2.21% or $0.105 during the last trading session, reaching $4.645. About 779,128 shares traded or 15.56% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since December 6, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $155.08 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. Maxim Group maintained the shares of ADMP in report on Monday, June 12 with “Buy” rating. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Thursday, July 21 with “Buy” rating. The firm earned “Buy” rating on Tuesday, September 12 by Raymond James. The firm has “Buy” rating given on Monday, August 21 by Maxim Group. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) earned “Buy” rating by Raymond James on Monday, December 4. Maxim Group initiated the shares of ADMP in report on Tuesday, December 1 with “Buy” rating.

More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Benzinga.com which released: “36 Biggest Movers From Yesterday” on December 06, 2017, also Nasdaq.com with their article: “Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors …” published on December 01, 2017, Globenewswire.com published: “Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND …” on December 04, 2017. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: Seekingalpha.com and their article: “Adamis Pharmaceuticals: A Rocket Still On The Launchpad” published on November 30, 2017 as well as Seekingalpha.com‘s news article titled: “Watch These December Biotech Catalysts” with publication date: December 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.